PanTheryx, a Boulder, CO-based biotechnology company focused on addressing serious GI related health conditions, completed a $50m financing round.
Perceptive Advisors made the investment, which brings the total financing raised by PanTheryx to $170 million.
The company intends to use the funds to accelerate development of novel medical foods and biologics in its pipeline as well as support expansion of its existing line of nutritionals, including its flagship product, DiaResQ.
Founded in 2007 by Mark Braman, CEO, PanTheryx provides a pipeline of novel candidates for addressing C. difficile infections, Crohn’s Disease, Ulcerative Colitis, and managing GI related side effects of cancer therapies. Rather than developing de novo molecules with a single target, the company’s candidates are being developed with bioactive backbones that contains multiple molecules with complementary mechanisms of action.
The company has production facilities in Phoenix, AZ and Ripon, CA.